Found 7 matching trials
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer
PHASE1ASK120067 Tablets is a Epidermal Growth Factor Receptor (EGFR) mutation sel...
Location
Chinese Academy of Medical Sciences
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
PHASE3To assess the efficacy and safety of ASK120067 versus a standard of care ep...
Status
Active Not Recruiting
Location
Chinese Academy of Medical Sciences
Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole
PHASE1To evaluate the effects of oral administration rifampicin or itraconazole c...
Location
Drum Tower Hospital of Nanjing University School of Medical
Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
PHASE2Patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell...
Location
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067
PHASE1This study is the first-in-human of ASKC202, which is an open-label, non-ra...
Location
The First Affiliated Hospital of Zhengzhou University
A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.
PHASE2A prospective, controlled Phase II clinical study on the efficacy and safet...
Location
Multiple Locations
Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects
PHASE1To evaluate the pharmacokinetic characteristics of ASK120067 and CCB4580030...
Location
The Second Affiliated Hospital of Zhejiang University School of Medicine